The strengths and weaknesses of the final CAR-T cell-infused product are inherent to live drugs

Ann Oncol. 2025 Jul;36(7):711. doi: 10.1016/j.annonc.2025.04.008. Epub 2025 Apr 25.

Authors

J-M Michot¹, C Bigenwald²

Affiliations

¹ Gustave Roussy, Department of Hematology, Villejuif, France. Electronic address: jean-marie.michot@gustaveroussy.fr.
² Gustave Roussy, Department of Hematology, Villejuif, France.

PMID: 40288677
DOI: 10.1016/j.annonc.2025.04.008

No abstract available

Publication types

Editorial